Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Start price
21.08.23
/
50%
€762.50
Target price
21.08.24
€910.85
Performance (%)
39.08%
End price
22.08.24
€1,060.5
Summary
This prediction ended on 22.08.24 with a price of €1,060.5. With a performance of 39.08% the BUY prediction by Canaccord_Genuity_Gr was a big success. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.156% | -0.156% | -1.233% |
| iShares Core DAX® | -0.436% | 1.181% | 14.210% |
| iShares Nasdaq 100 | 0.854% | 1.475% | 5.797% |
| iShares Nikkei 225® | 2.652% | 6.401% | 19.133% |
| iShares S&P 500 | 1.190% | 1.169% | 2.686% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $992.00 price target on the stock, up previously from $720.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten